Norway does not need one access clock. It needs better handoffs.

The Norwegian debate about access to new health technologies often starts with a reasonable question: how long does it take?

The problem is that “time to access” is not one clock. It can mean time before a supplier submits evidence, time in validation and assessment, time in negotiation and decision-making, time from national decision to operational availability, or time from referral to treatment. Norway's priority-setting white paper separates several of these intervals, while the OECD warns that apparently similar waiting-time measures can start at different events across countries (Meld. St. 21 (2024–2025); OECD, 2025).

Compressing these intervals into one number makes a simple headline, but it removes accountability: which actor owns which delay, what evidence would explain it, and where a handoff failed all become harder to see.

A more useful reform agenda would make five interfaces visible without weakening public authority over priority-setting.

The framework below is mine. The four stakeholder perspectives I draw on each corroborate one part from its own vantage point; none endorses the framework as a whole. KS's interim digitalisation-and-coordination submission calls for retaining today's structure and strengthening coordination, saying the problem lies “not primarily” in the organisational model but in insufficient implementation of those measures (KS). Its argument concerns digitalisation and coordination, not the five-interface framework proposed here.

1. European clinical evidence must hand off cleanly to Norwegian priority decisions

The EU Health Technology Assessment Regulation creates a shared clinical evidence layer. A Joint Clinical Assessment (JCA) analyses relative effects and the certainty of those effects. It does not make value judgements or conclude on overall clinical added value. National authorities must give due consideration to the JCA where the Regulation applies, but its scientific content is not a binding national decision (Regulation (EU) 2021/2282).

Norway has implemented the Regulation through the EEA framework. DMP is responsible for Norway's PICO input for medicines covered by HTAR, while national conclusions, health-economic assessment, pricing and reimbursement, health-service financing and introduction decisions remain Norwegian (Nye metoder, updated 13 March 2026; DMP; Meld. St. 21).

By 27 May 2026, Nye metoder had introduced a clinical-network PICO-input routine and was adapting its request processes to HTAR, with the first requests as pilots (Nye metoder action plan, 27 May 2026).

This is not a wall between Europe and Norway; it is a division of labour. The practical bridge is an early handoff document stating:

• which PICO questions the JCA will answer;
• which Norwegian comparators or subgroups may require additional analysis;
• which uncertainties remain after the JCA;
• which economic, budget and implementation evidence Norway still needs; and
• who owns each next step and deadline.

Early alignment has measured stakes. In reviewed EU experience with parallel regulatory–HTA advice, full agreement was highest on patient population (77%) and disagreement peaked on the study comparator (30%), and 85% of applications that followed the EMA's early scientific advice were granted marketing authorisation, against 41% that did not. These are associations from 2008–2015 EU cohorts, not guarantees (Ibargoyen-Roteta et al., 2022). The comparator, in other words, is where handoffs have historically failed first, exactly what an early handoff document must catch.

The aim is not to import a European value judgement. HTAR bars national resubmission of evidence already supplied at Union level, but permits complementary national clinical analyses for different populations, comparators, outcomes or nationally required methods. This boundary protects the decision only Norway can make (Regulation (EU) 2021/2282).

2. Supplier readiness and public processing need separate clocks

A September 2022 Nye metoder snapshot identified 164 pharmaceutical assessment assignments waiting because manufacturers had not submitted documentation. From May 2023, the system moved from automatic method alerts to supplier-initiated requests for pharmaceutical assessments (Nye metoder, 2022; Meld. St. 21).

That historical snapshot is not a current backlog measure, but it shows why supplier readiness and public assessment are different accountabilities connected by a handoff, not one clock.

The current action plan makes that handoff more explicit: suppliers should notify DMP at least three months before submission, and Bestillerforum normally cancels commissions after 12 months without documentation. These are process rules, not evidence of shorter elapsed time (Nye metoder action plan).

Norway has also introduced simplified pathways: when a clinical specialist group judges efficacy and adverse effects comparable for most patients, Bestillerforum can commission a price note rather than a method assessment. Nye metoder's 2025 annual summary reports mean times from marketing authorisation to a Beslutningsforum decision of 65 days for PD-(L)1 price-note cases (n=12), 154 days for early-comparability price-note cases (n=18), and 382 days for method-assessment-plus-price-note cases in the defined post-April-2023 cohort treated through December 2025 (n=17) (Nye metoder, Årsoppsummering 2025).

For those 17 full-HTA cases, suppliers averaged 135 days to initial documentation and 73 more days for supplements; DMP averaged 133 assessment days. Twelve cases with earlier authorisation were excluded, and the reported phases may overlap (Nye metoder, Årsoppsummering 2025). Time accrued on both sides of that interface.

These are descriptive averages from different pathways and cohorts, not causal estimates or a league table. Report the pathway, cohort, start event, stop event and sample size before interpreting any timing number.

I would use a public clock dictionary with at least five intervals:

This avoids a blame exercise: suppliers answer for evidence readiness, public bodies for transparent processing, and both can see the dependencies at the interface.

3. A saved minute is not yet health-system capacity

Workforce claims matter because Norway cannot treat personnel as an unlimited input. The priority-setting white paper says personnel consequences must be specifically assessed within the resource criterion. DMP's current submission guidance requires resource quantities and unit costs to be presented and justified separately (Meld. St. 21; DMP submission guideline, updated 6 July 2026).

But the common shortcut, minutes saved multiplied by activity volume, does not prove usable capacity. I would first test seven things: task, comparator, staff group, setting, time horizon, implementation burden, and any transfer of work across hospitals, municipalities, patients or caregivers.

Then I would report the claim as a five-link evidence chain:

Each link is an empirical question. Norway's Health Personnel Commission warned that micro-level time savings can be absorbed at system level. An international health-economic framework likewise separates process effects, costs and health outcomes when resources are constrained (NOU 2023:4; Thokala et al., 2025).

A Swedish controlled interrupted time-series study offers the caution: fewer inpatient days after a care-coordination reform, but no robust reform effect on readmissions, outpatient visits or mortality. Saved care days and patient outcomes were separate endpoints (Spangler, Linder and Winblad, 2023).

The chain improves evidence on both sides: developers learn what to measure beyond task minutes, and HTA bodies and service leaders can separate an operational hypothesis from demonstrated capacity or patient benefit.

4. A national “yes” needs a delivery-readiness handoff

A positive national introduction decision makes a method available for patients who meet its conditions, but it does not create an automatic individual entitlement: the treating professional must still decide whether the method is right for the patient (Expert Group on Access and Priority-Setting, 2024; Meld. St. 21).

A national decision is also not the same event as routine delivery: the pre-decision dossier may describe population size, resource use, uncertainty and budget impact, but none of that proves every delivery condition is ready (DMP submission guideline).

National policy nevertheless sets same-date access for all eligible patients as a goal once a method is introduced, without awaiting guideline revision. That is policy intent, not evidence that routine delivery is uniformly realised (Meld. St. 21).

I propose a short readiness note alongside major introduction decisions, reporting eight domains separately:

1. clinical ownership;
2. eligible population and start/stop rules;
3. pathway integration;
4. staffing and capacity;
5. procurement or funding;
6. data availability;
7. geographic and socioeconomic equity; and
8. monitoring or reassessment.

Domain five is where this turns concrete. Drammen kommune's health administration says municipalities cannot realistically take on health-trust tasks without increased block-grant funding or arrangements in which funding follows the patient more closely (Drammen kommune). That is one municipality naming a condition, not a national settlement, but it is exactly the dependency a readiness note should surface.

The note would not reopen the priority decision. It shows which delivery dependencies are ready, which remain open, who owns them, and when they will be reviewed, making the handoff from national policy to clinical operations visible without confusing eligibility, individual clinical judgement and delivery.

5. Dialogue should improve evidence, not blur decision rights

Norway already has advisory dialogue mechanisms. Nye metoder's 2025 annual summary describes separate reference groups for medicines and non-medicines, and documents limitations in follow-up. The national strategy for personalised medicine emphasises collaboration alongside conflict-of-interest governance. Formal priority responsibility remains with public authorities that carry provision and financing responsibility (Nye metoder, 2026; National Strategy for Personalised Medicine 2023–2030; Meld. St. 21).

The bridge should therefore be designed, not improvised. I would establish a legitimate-engagement charter for non-product system and methods dialogue. Inside the charter: evidence standards, PICO coordination, feasibility of data collection, workforce measurement, implementation dependencies, evaluation design and learning from completed cases. Outside it: active appraisals, case-specific price negotiation, voting, co-decision and final priority decisions.

A charter that only regulates industry would miss half the legitimacy problem. Mental Helse adds a legitimacy condition: real and binding participation by user, patient and carer organisations, with lived experience integrated into the decision basis rather than merely heard (Mental Helse). That strengthens the decision basis without extending participation into voting or final priority decisions.

That boundary protects both parties. Public bodies retain independence and legitimacy. Responsible industry gains a clearer route to contribute evidence and operational knowledge without being mistaken for the decision-maker. NHO Geneo argues that public–private teamplay can contribute to a more robust, accessible and sustainable health service (NHO Geneo); this is advocacy, not evidence that those outcomes will follow. That distinction is the charter working: industry gets a real route to contribute, and its claims meet the same test as everyone else's.

From debate to a shared handoff scorecard

The practical next step is modest: for every major interface, publish six fields:

1. start event;
2. stop event;
3. accountable owner;
4. evidence required;
5. uncertainty or external dependency; and
6. the next handoff.

Any owner of an interface can publish those six fields now; no national redesign is required.

The scorecard would not resolve every disagreement about evidence, price, priority or implementation; it would make those disagreements more precise.

The timing matters: Helsereformutvalget is mandated to propose new models for financing, governance and organisation of Norway's health and care services, with its report due 1 November 2026 (Regjeringen, Helsereformutvalget). The coming reform cycle will redraw accountability interfaces. The scorecard is a way to redraw them deliberately.

Norway does not need collaboration that softens public decision rights, nor accountability language that treats every interface as a wall. It needs handoffs strong enough that each side can do its job, while remaining transparent enough that patients, clinicians, decision-makers and suppliers can see where the next responsibility begins.